DelveInsight’s “Sepsis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Sepsis, historical and forecasted epidemiology as well as the Sepsis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Sepsis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sepsis Market Forecast
Some of the key facts of the Sepsis Market Report:
-
Among the 7MM countries Sepsis market size was valued approximately USD 2,807 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
-
In April 2024, Enlivex Therapeutics released favorable top-line results regarding the safety and efficacy of Allocetra, an off-the-shelf cell therapy, from its Phase II clinical trial for sepsis treatment. This placebo-controlled and randomized trial aims to establish the ideal dosage of Allocetra in conjunction with the standard of care for sepsis arising from diverse infections.
-
In January 2024, Matisse Pharmaceuticals has released promising initial findings from the HistoSeps study, which focused on assessing the safety, tolerability, and pharmacokinetics of M6229 for sepsis treatment. This pioneering human trial, carried out at the Amsterdam University Medical Center, included ten severely ill patients and achieved its primary goals. The results indicated favorable safety and tolerability profiles, as well as pharmacokinetics that closely aligned with the dosage administered intravenously over a six-hour period.
-
In 2022, the 7MM documented 3,543,995 cases of sepsis, and projections indicate an anticipated increase by 2032. Among these cases, the United States held the largest share, contributing 55% to the overall sepsis population, amounting to 1,938,855 cases in 2022.
-
In 2022, the combined total of sepsis cases in the EU4 and the UK reached 1,210,184, and there is an anticipated increase by 2032. Among the EU countries, Germany had the highest share in the sepsis population, recording 322,020 cases in 2022.
-
In Japan, there were 394,956 new cases of sepsis reported. The epidemiological data reveals that the incidence in Japan constituted 11% of the overall patient pool in the 7MM in 2022.
-
Key Sepsis Companies: Vivacelle Bio, Inotrem SA, Enlivex Therapeutics, Tianjin Chasesun Pharmaceutical, Basilea Pharmaceutica, Artcline GmbH, Vivacelle Bio, RWTH Aachen University, Novartis, University of New Mexico, and others
-
Key Sepsis Therapies: VBI-S, Nangibotide, Allocetra,16mg，KB, Ceftobiprole medocaril, ARTICE, VBI-S, Pentaglobin®/Standard of Care, TIN816 70, Angiotensin II, and others
-
The Sepsis epidemiology based on gender analyzed that in the 7MM, the majority of patient pool were males as compared to females whereas in the US female population dominated the Sepsis incident pool
-
The Sepsis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sepsis pipeline products will significantly revolutionize the Sepsis market dynamics.
Sepsis Overview
Sepsis is a severe and potentially life-threatening condition that occurs when the body’s response to an infection leads to systemic inflammation. The immune system’s response to infection can sometimes become overactive, triggering widespread inflammation that can result in organ dysfunction or failure.
Get a Free sample for the Sepsis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/sepsis-market
Sepsis Epidemiology
Sepsis is a potentially life-threatening condition that occurs when the body’s response to an infection causes inflammation throughout the body. Normally, the body’s immune system releases chemicals into the bloodstream to fight off an infection. However, in sepsis, this immune response triggers widespread inflammation, leading to blood clot formation and reduced blood flow to vital organs, such as the brain, heart, and kidneys.
Sepsis Epidemiology Segmentation:
The Sepsis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Total Prevalence of Sepsis
-
Prevalent Cases of Sepsis by severity
-
Gender-specific Prevalence of Sepsis
-
Diagnosed Cases of Episodic and Chronic Sepsis
Download the report to understand which factors are driving Sepsis epidemiology trends @ Sepsis Epidemiology Forecast
Sepsis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sepsis market or expected to get launched during the study period. The analysis covers Sepsis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Sepsis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Sepsis Therapies and Key Companies
-
VBI-S: Vivacelle Bio
-
Nangibotide: Inotrem SA
-
Allocetra: Enlivex Therapeutics
-
16mg，KB: Tianjin Chasesun Pharmaceutical
-
Ceftobiprole medocaril: Basilea Pharmaceutica
-
ARTICE: Artcline GmbH
-
VBI-S: Vivacelle Bio
-
Pentaglobin®/Standard of Care: RWTH Aachen University
-
TIN816 70: Novartis
-
Angiotensin II: University of New Mexico
Discover more about therapies set to grab major Sepsis market share @ Sepsis Treatment Landscape
Scope of the Sepsis Market Report
-
Study Period: 2019–2032
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Sepsis Companies: Vivacelle Bio, Inotrem SA, Enlivex Therapeutics,Tianjin Chasesun Pharmaceutical, Basilea Pharmaceutica, Artcline GmbH, Vivacelle Bio, RWTH Aachen University, Novartis, University of New Mexico, and others
-
Key Sepsis Therapies: VBI-S, Nangibotide, Allocetra, 16mg，KB, Ceftobiprole medocaril, ARTICE, VBI-S, Pentaglobin®/Standard of Care, TIN816 70, Angiotensin II, and others
-
Sepsis Therapeutic Assessment: Sepsis current marketed and Sepsis emerging therapies
-
Sepsis Market Dynamics: Sepsis market drivers and Sepsis market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Sepsis Unmet Needs, KOL’s views, Analyst’s views, Sepsis Market Access and Reimbursement
To know more about Sepsis companies working in the treatment market, visit @ Sepsis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Sepsis Market Report Introduction
2. Executive Summary for Sepsis
3. SWOT analysis of Sepsis
4. Sepsis Patient Share (%) Overview at a Glance
5. Sepsis Market Overview at a Glance
6. Sepsis Disease Background and Overview
7. Sepsis Epidemiology and Patient Population
8. Country-Specific Patient Population of Sepsis
9. Sepsis Current Treatment and Medical Practices
10. Sepsis Unmet Needs
11. Sepsis Emerging Therapies
12. Sepsis Market Outlook
13. Country-Wise Sepsis Market Analysis (2019–2032)
14. Sepsis Market Access and Reimbursement of Therapies
15. Sepsis Market Drivers
16. Sepsis Market Barriers
17. Sepsis Appendix
18. Sepsis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/